Fueling The Advancement of Healthcare Technology
With new technologies transforming early detection and making prognosis/disease monitoring a critical element of patient care, the MedTech, Tools & Diagnostics sector is making great advances from research to clinical, elevating the category as a trusted outsourcing partner for Biopharma.
Our team partners with established and emerging companies as a trusted advisor across capital formation and M&A strategy.
Recent transactions
MedTech, Tools & Diagnostics Team
Our leading team of professionals leverages their knowledge, experience and singular healthcare focus to help our clients achieve their financing and strategic objectives.
Andrew Gitkin is a Senior Managing Director in Investment Banking at Leerink Partners.
Andrew joined the Firm in 2024 from Raymond James & Associates where he most recently served as a Senior Managing Director and Vice Chairman in the healthcare investment banking group. He brings over 25 years of healthcare-focused experience specializing in the biopharma and medical device sectors, including more than 100 transactions across M&A advisory, equity and equity linked financings. Prior to Raymond James, he served as a Managing Director and Head of West Coast Biotechnology at PiperJaffray & Company, and Senior Vice President at Moelis & Company. Andrew’s previous experience also includes roles as a Vice President of Tavistock Life Sciences and leading a biotechnology start-up. He started his career in the Equity Research Departments of SalomonSmithBarney and UBS.
He is a member of the UCLA Health System Board, and he earned his BBA from Emory University.
Tim Hotchandani is a Senior Managing Director of Healthcare Services & Technology Investment Banking.
Prior to joining Leerink Partners, Mr. Hotchandani served as a Managing Director at Rothschild & Co, specializing in the coverage of Life Science Technology companies globally. Previously, he was a Managing Director at Deutsche Bank and began his career as an investment banking analyst at Lehman Brothers and Thomas Weisel Partners LLC.
Mr. Hotchandani earned a Bachelor of Business and Economics from the University of Wisconsin-Madison. He is also a CFA® charterholder.
Bernhard Sakmann, M.D., is a Senior Managing Director in Investment Banking at Leerink Partners covering the Medical Technology and Life Science Tools and Diagnostics sectors.
Prior to joining the Firm in 2024, Bernhard was most recently a Senior Managing Director at Evercore, providing strategic and financial advice to life science companies with a focus on medical technology and life science tools and diagnostics. Prior to joining Evercore in 2014, Bernhard spent over a decade in healthcare investment banking and in management consulting with Citigroup, Lehman Brothers and Oliver Wyman in New York and in London. Notable transactions for which Bernhard has been an adviser include Philips on its acquisitions of Biotelemetry and Capsule, GE on its acquisition of BK Medical and spin of GE Healthcare, Abbott on its acquisitions of St Jude Medical and Alere, Terumo on its acquisitions of Sequent Medical and Bolton Medical, Immucor on its sale to Werfen, Decipher on its sale to Veracyte, ArcherDx on its sale to Invitae, Brooks Automation on its acquisitions of Genewiz and BioStorage Technologies, among many others.
He received a Doctorate in Medicine from Ludwig-Maximilians-University, Munich, Germany, a B.M. BCh. from Oxford University, UK, and a B.A. and an M.A. in Natural Sciences from Cambridge University, UK.
Justin Reed is a Managing Director at Leerink Partners where he is focused on advising companies in the medical device sector on M&A and public and private equity offerings.
Prior to joining the Firm in 2024, Justin was most recently Managing Director at Evercore in the strategic advisory business. While at Evercore he advised on many transactions across the medical device sector including GE Healthcare’s spin from GE, GE’s acquisition of BK Medical, Lunit’s acquisition of Volpara, Philips’ acquisition of Biotelemetry and Capsule, SHINE Technologies acquisition of Phoenix, Abbott on the sale of Angio-Seal to Terumo and the sale of Epocal to Siemens Healthineers, and Terumo’s acquisition of Sequent medical. Justin was previously the founder of several medical device companies and holds multiple patents and academic publications for medical device technologies.
He earned his M.B.A. from Berkeley Haas School of Business, Master of Science in Physics from the University of Washington, and a Bachelor of Science in Physics from the University of Washington.
